menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Let’s Examine Collaborative Patient Management in ASCVD Risk Reduction

Join expert faculty for evidence-based collaborative options to reduce ASCVD event burden in your statin-treated patients with high residual CV risk.

Live Broadcast
1.00 available credits
Information
May 12, 2022
07:00 PM - 08:00 PM EDT
Online
ReachMD Healthcare Image
Choose a format
Details
Presenters
Comments
  • Overview

    We now have evidence-based options to reduce atherosclerotic cardiovascular disease (ASCVD) event burden beyond any previously available therapy. A pragmatic approach that addresses residual cardiovascular (CV) risk across a variety of risk factors and that goes beyond LDL-C lowering therapies is needed to optimally manage patients with or at high risk of ASCVD. Pharmacists treating these patients require review of recent data and guidelines so they can incorporate these findings into clinical practice. Join us to ensure you’re keeping up with the science and giving your patients the best care.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
    Clinical Pharmacist Specialist, Primary Care
    Grady Health System
    Atlanta, GA

    No relationships reported.

    Faculty:
    Charles P. Vega, MD
    Clinical Professor, Family Medicine
    Director, UC Irvine Program in Medical Education for the Latino Community (PRIME-LC), Family Medicine
    Associate Dean, School of Medicine
    University of California, Irvine
    Orange, CA

    Consulting Fees: GlaxoSmithKline, Johnson and Johnson

    Reviewers/Content Planners/Authors

    • Sean T. Barrett has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Kate Nagele has nothing to disclose.
    • Mario Trucillo, PhD, has nothing to disclose.
    • Kathy Wickman, BSN, has nothing to disclose.
  • Learning Objectives

    The goal of this activity is to enable effective collaboration and communication between the members of the professional teams who care for patients with ASCVD risk. After participating in this educational activity, participants should be better able to:

    • Discuss biologic effects of omega-3s, their mechanisms of action, and what makes prescription icosapent ethyl different
    • Engage with physicians to interpret the recent major clinical trials on omega-3s and their clinical implications for patients
    • Have greater competence to discuss the use of icosapent ethyl and define the shortfalls of dietary supplements for ASCVD management
  • Target Audience

    This activity is designed to meet the educational needs of primary care physicians, pharmacists, and other members of the interprofessional team who are involved in the management of patients with ASCVD risk.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0  AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 60 minutes of nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    This curriculum has been approved for 1.0 contact hours (.1 CEUs) by Global Learning Collaborative (GLC). GLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Universal Activity Number for this program is UAN JA0006235-0000-22-011-L01-P. This learning activity is live. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Details
Presenters
Comments
Recommended
  • Overview

    We now have evidence-based options to reduce atherosclerotic cardiovascular disease (ASCVD) event burden beyond any previously available therapy. A pragmatic approach that addresses residual cardiovascular (CV) risk across a variety of risk factors and that goes beyond LDL-C lowering therapies is needed to optimally manage patients with or at high risk of ASCVD. Pharmacists treating these patients require review of recent data and guidelines so they can incorporate these findings into clinical practice. Join us to ensure you’re keeping up with the science and giving your patients the best care.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
    Clinical Pharmacist Specialist, Primary Care
    Grady Health System
    Atlanta, GA

    No relationships reported.

    Faculty:
    Charles P. Vega, MD
    Clinical Professor, Family Medicine
    Director, UC Irvine Program in Medical Education for the Latino Community (PRIME-LC), Family Medicine
    Associate Dean, School of Medicine
    University of California, Irvine
    Orange, CA

    Consulting Fees: GlaxoSmithKline, Johnson and Johnson

    Reviewers/Content Planners/Authors

    • Sean T. Barrett has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Kate Nagele has nothing to disclose.
    • Mario Trucillo, PhD, has nothing to disclose.
    • Kathy Wickman, BSN, has nothing to disclose.
  • Learning Objectives

    The goal of this activity is to enable effective collaboration and communication between the members of the professional teams who care for patients with ASCVD risk. After participating in this educational activity, participants should be better able to:

    • Discuss biologic effects of omega-3s, their mechanisms of action, and what makes prescription icosapent ethyl different
    • Engage with physicians to interpret the recent major clinical trials on omega-3s and their clinical implications for patients
    • Have greater competence to discuss the use of icosapent ethyl and define the shortfalls of dietary supplements for ASCVD management
  • Target Audience

    This activity is designed to meet the educational needs of primary care physicians, pharmacists, and other members of the interprofessional team who are involved in the management of patients with ASCVD risk.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0  AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 60 minutes of nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    This curriculum has been approved for 1.0 contact hours (.1 CEUs) by Global Learning Collaborative (GLC). GLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Universal Activity Number for this program is UAN JA0006235-0000-22-011-L01-P. This learning activity is live. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Schedule22 May 2022
Webpack App